Division of Imaging Sciences, King's College London British Heart Foundation Centre, Biomedical Research Centre of Guy's and St. Thomas' Hospital, King's College London, National Health Service Foundation Trust, Lambeth Place Road, London SE1 7EH, England.
Radiology. 2011 Sep;260(3):680-8. doi: 10.1148/radiol.11102327. Epub 2011 May 25.
To compare the image quality and diagnostic performance of a contrast agent-specific inversion-recovery (IR) steady-state free precession (SSFP) magnetic resonance (MR) imaging sequence performed by using an intravascular contrast agent (gadofosveset trisodium) with those of a commonly used T2-prepared SSFP sequence performed by using an extravascular (gadopentetate dimeglumine) and an intravascular (gadofosveset trisodium) contrast agent in patients with congenital heart disease (CHD).
The local ethics committee and the United Kingdom Medicines and Healthcare products Regulatory Agency approved this study. Patient informed consent was obtained. Twenty-three patients with CHD were examined by using a 1.5-T MR imaging unit and a 32-channel coil. Gadopentetate dimeglumine and gadofosveset trisodium were used in the same patient on consecutive days. Vessel wall sharpness, contrast-to-noise ratios (CNRs), image quality, and diagnostic performance achieved by using the IR SSFP sequence with gadofosveset trisodium were compared with those achieved by using the T2-prepared SSFP sequence with gadopentetate dimeglumine and gadofosveset trisodium and with those achieved at respective contrast material-enhanced MR angiographic examinations. The Wilcoxon rank sum test was used to compare categoric variables; t tests were used to compare continuous variables.
Use of the IR SSFP sequence with gadofosveset trisodium significantly improved vessel wall sharpness, CNRs, and image quality (P < .05 for all) for all investigated intra- and extracardiac structures compared with the T2-prepared SSFP sequence with gadopentetate dimeglumine and gadofosveset trisodium and the respective contrast-enhanced MR angiographic examinations. With use of the IR SSFP sequence with gadofosveset trisodium, new, unsuspected diseases (five [22%] of 23) were diagnosed, while other diseases could be excluded (15 [65%] of 23). Information available from echocardiography (n = 23), conventional angiography (n = 4), and/or surgery (n = 1) confirmed all diagnoses.
IR SSFP with gadofosveset trisodium improved image quality and diagnostic performance, allowing a more accurate and complete assessment of cardiovascular anatomy in patients with CHD compared with T2-prepared SSFP with gadopentetate dimeglumine and gadofosveset trisodium and respective contrast-enhanced MR angiographic examinations.
比较使用血管内造影剂(钆夫酸葡胺)对比剂特异反转恢复(IR)稳态自由进动(SSFP)磁共振(MR)成像序列与使用血管外(钆喷酸葡胺)和血管内(钆夫酸葡胺)造影剂的常用 T2 准备 SSFP 序列的图像质量和诊断性能,以评估先天性心脏病(CHD)患者的图像质量和诊断性能。
本研究经当地伦理委员会和英国药品和保健产品监管局批准。所有患者均签署知情同意书。23 例 CHD 患者采用 1.5T MR 成像仪和 32 通道线圈进行检查。钆喷酸葡胺和钆夫酸葡胺在同一位患者中连续使用。对比剂特异反转恢复 SSFP 序列(使用钆夫酸葡胺)与 T2 准备 SSFP 序列(使用钆喷酸葡胺和钆夫酸葡胺)以及各自的对比增强 MR 血管造影检查的血管壁锐利度、对比噪声比(CNR)、图像质量和诊断性能进行比较。采用 Wilcoxon 秩和检验比较分类变量;采用 t 检验比较连续变量。
与 T2 准备 SSFP 序列(使用钆喷酸葡胺和钆夫酸葡胺)和各自的对比增强 MR 血管造影检查相比,使用钆夫酸葡胺的对比剂特异反转恢复 SSFP 序列可显著提高所有研究的心脏内和心脏外结构的血管壁锐利度、CNR 和图像质量(所有 P 值均<.05)。使用钆夫酸葡胺的对比剂特异反转恢复 SSFP 序列可诊断新的、意外的疾病(23 例中 5 例,22%),并排除其他疾病(23 例中 15 例,65%)。超声心动图(n=23)、常规血管造影(n=4)和/或手术(n=1)提供的信息可确认所有诊断。
与 T2 准备 SSFP 序列(使用钆喷酸葡胺和钆夫酸葡胺)和各自的对比增强 MR 血管造影检查相比,使用钆夫酸葡胺的对比剂特异反转恢复 SSFP 可改善图像质量和诊断性能,从而更准确、更全面地评估 CHD 患者的心血管解剖结构。